Companies/Whitehawk Therapeutics Inc

Company profile

Whitehawk Therapeutics Inc

NASDAQ: WHWK · Healthcare · Biotechnology

PublicHQ Pacific Palisades, CACIK 0001422142Reports USD

#667 of 1,394 Healthcare companies by revenuebottom-quartile growth

EA Score

50D

FH 53DQ 61GM 16SS 53

v0.1 · 65/100 weight · provisional

↑ balance-sheet leverage, Altman-Z · ↓ Piotroski F, growth stability

Methodology →

Revenue TTM

Rev growth YoY (TTM)

-100.0%

Net income (FY)

-$20.6M

Employees

Market cap

$207.2M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$7.1M$7.1M2025

Net income-$20.6M-$20.6M2025

Operating income-$114.4M-$114.4M2025

Total assets$150.8M$150.8M2025

Liabilities$14.5M$14.5M2025

Equity$136.3M$136.3M2025

Revenue trend

FY2018 – FY2025 · USD

$20.2M

FY18

FY20

$15.0M

FY20

$1.1M

FY21

$15.2M

FY22

$24.4M

FY23

$26.0M

FY24

$7.1M

FY25

Revenue by segment

Filed disclosures · FY2025

By product

Product100%

By geography

Not disclosed.

The read

Whitehawk Therapeutics Inc booked $7.1M in FY2025 revenue, contracting 73% year over year — slower than 87% of Healthcare companies we track, at a -288.3% net margin.

Peers · Healthcare

Arcturus Therapeutics Holdings Inc.49D Fulcrum Therapeutics, Inc.58C KORU Medical Systems, Inc.72B Profound Medical Corp.44D

Key facts

CEODavid J. Lennon

SectorHealthcare

IndustryBiotechnology

HeadquartersPacific Palisades, CA

ExchangeNASDAQ: WHWK

Employees40

IPO date2017-08-01

Latest filings

8-K2026-06-12 8-K2026-05-21 8-K2026-05-13 10-Q2026-05-07 8-K2026-05-07 DEF 14A2026-04-28 8-K2026-03-12 10-K2026-03-12

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.